Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Propafenone Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Propafenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 16, 2019
Lead Product(s) : Propafenone Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propafenone Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Propafenone in the Treatment of Atrial Fibrillation
Details : Propafenone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2018
Lead Product(s) : Propafenone Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propafenone Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites
Details : Propafenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arrhythmias, Cardiac.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2013
Lead Product(s) : Propafenone Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable